Get the Stockscreener App
190.28
0.29%
-0.55
After Hours:
190.28
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $190.28, with a volume of 3.78M.
It is down -0.29% in the last 24 hours and up +2.64% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$190.83
Open:
$191.4
24h Volume:
3.78M
Relative Volume:
0.59
Market Cap:
$336.11B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
80.97
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+0.54%
1M Performance:
+2.64%
6M Performance:
+11.73%
1Y Performance:
+4.45%
1-Day Range:
$188.53
$191.40
1-Week Range:
$184.63
$192.24
52-Week Range:
$163.81
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
|
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie’s Phase 3 Study on Telisotuzumab Vedotin: A Potential Game-Changer in NSCLC Treatment - The Globe and Mail
What analysts say about AbbVie Inc. stockGame-changing returns - PrintWeekIndia
Is AbbVie Inc. a good long term investmentExplosive portfolio gains - PrintWeekIndia
AbbVie’s Phase 3 Study on Upadacitinib for SLE: A Potential Game Changer? - The Globe and Mail
AbbVie’s Latest Clinical Study on Glaucoma Gel Stent: Market Implications - The Globe and Mail
Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.
What drives AbbVie Inc. stock priceExceptional portfolio growth - PrintWeekIndia
MHRA approves AbbVie’s Elahere - The Pharma Letter
AbbVie’s Pediatric Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks
AbbVie’s Long-term Study on Bimatoprost SR: Market Implications and Study Insights - TipRanks
September 5th Options Now Available For AbbVie (ABBV) - Nasdaq
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
The 3 Things That Matter for AbbVie Now - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Staar Surgical (STAA) and Universal Health (UHS) - The Globe and Mail
Endometriosis Drugs Market Growing at Robust Expansion of the Decade: AbbVie, Pfizer, Astellas Pharma - openPR.com
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know - Yahoo Finance
AbbVie Inc. Stock Analysis and ForecastBreakthrough profits - jammulinksnews.com
Lip Fillers Market Is Booming So Rapidly 2025-2032Allergan (AbbVie Inc.), Galderma S.A., Merz Pharma - openPR.com
Why AbbVie (ABBV) is a Strong Buy for Diversified Portfolios in a Volatile Market - AInvest
4 Reasons To Buy AbbVie (NYSE:ABBV) - Seeking Alpha
How Will AbbVie's Neuroscience Franchise Perform In Q2 Earnings? - Barchart.com
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - Yahoo Finance
IGI, Abbvie team up to advance myeloma treatment ISB 2001 - Rare Cancer News
BOTOX® Cosmetic (onabotulinumtoxinA) Selects This Year's Entrepreneurs for The Confidence Project - AbbVie News Center
Lobbying Update: $1,160,000 of ABBVIE INC. lobbying was just disclosed - Quiver Quantitative
AbbVie's Allergan wins $56 million in Botox patent fight - Crain's Chicago Business
AbbVie unit wins $56 mln in US patent trial against Botox rival - Reuters
AbbVie Unit Wins $56 Million from Revance Over Botox Patents (1) - Bloomberg Law News
Stacey McCullough: I’m Thrilled to Join AbbVie Oncology Working in Market Access - Oncodaily
Non-Small Cell Lung Cancer Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca - Barchart.com
AbbVie’s Promising Phase 2 Study on ADPKD Treatment: What Investors Need to Know - The Globe and Mail
AbbVie's Q1 2025 Earnings Surge 6.5% Year-Over-Year - AInvest
AbbVie Stock (ABBV) Opinions on Recent Price Surge and Sales Growth - Quiver Quantitative
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT - MSN
AbbVie’s Phase 3 Study on Atogepant: A Potential Game-Changer for Pediatric Migraine Prevention - TipRanks
Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector - MSN
Rothschild Raises AbbVie (ABBV) Price Target, Maintains Buy Rating - MSN
AbbVie Inc. stock underperforms Friday when compared to competitors - MarketWatch
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):